基于宏观环的药物的开发中被忽视的并发症和机遇: "同源性开关"
Isabelle J Smith1, Simon M Popovic1, John A Gladysz1
1Department of Chemistry, Texas A&M University, PO Box 30012, College Station, Texas 77842-3012, United States.
Journal of the American Chemical Society
|February 26, 2026
概括
均体异体化,一个分子内外过程,转化宏观循环化合物. 这种形状变化产生了具有独特化学和生物特性的独特桥头配置,影响了药物设计和知识产权.
科学领域:
- 有机化学 有机化学
- 化学生物学 化学生物学
- 立体化学是一种立体化学.
背景情况:
- 宏观循环化合物表现出同型异体化,这是一个很少被研究的构造过程.
- 这种异质化有效地反转了分子,产生了各种桥头配置 (进,进;出,出;进,出;出,进).
- 预计这些不同的配置具有不同的化学和生物特征.
研究的目的:
- 在宏观循环系统中审查同型异构的基本方面.
- 探索这种现象对物理有机化学和化学生物学的含义.
- 确定在立体化学定义,药物设计和知识产权方面取得进展的机会.
主要方法:
- 审查现有的关于同源异构化文献.
- 对模型化合物 (E((CH2) n) 3E,n ≥ 10) 和宏观循环的分析.
- 探索物理有机化学和化学生物学之间的跨学科视角.
主要成果:
- 均体异体化导致具有潜在不同的性质的独特分子架构.
- 该研究将理论有机化学与化学生物学中的实际应用联系起来.
- 确定了改善立体化学控制和新药开发战略的机会.
结论:
- 了解同型异构化对于表征宏观循环化合物至关重要.
- 这种现象为药物发现和开发提供了新的途径.
- 可能影响药物化学中的知识产权景观.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
4.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.5K
Drug Discovery: Overview
12.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.3K
Principles of Drug Action
9.1K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
9.1K
Targets for Drug Action: Overview
10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K
Prodrugs
4.5K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
4.5K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
209
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209


